Protalix BioTherapeutics Inc PLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PLX is a good fit for your portfolio.
News
-
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
-
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
-
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
-
Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel
-
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
-
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Protalix BioTherapeutics Eligible for $20 Million Milestone Payment
-
Protalix BioTherapeutics, Chiesi Global Get FDA Approval for Elfabrio
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.44–1.53
- 52-Week Range
- $1.13–3.55
- Bid/Ask
- $1.46 / $1.50
- Market Cap
- $110.16 Mil
- Volume/Avg
- 3 / 428,007
Key Statistics
- Price/Earnings (Normalized)
- 46.82
- Price/Sales
- 1.75
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 197
- Website
- https://www.protalix.com
Valuation
|
Metric
|
PLX
|
|---|---|
Price/Earnings (Normalized) | 46.82 |
Price/Book Value | 2.88 |
Price/Sales | 1.75 |
Price/Cash Flow | 10.59 |
Price/Earnings
PLX
Financial Strength
|
Metric
|
PLX
|
|---|---|
Quick Ratio | 1.15 |
Current Ratio | 1.67 |
Interest Coverage | 4.44 |
Quick Ratio
PLX
Profitability
|
Metric
|
PLX
|
|---|---|
Return on Assets (Normalized) | 18.27% |
Return on Equity (Normalized) | 115.65% |
Return on Invested Capital (Normalized) | 35.04% |
Return on Assets
PLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kny | $454.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mcbsyf | $90.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nrgxl | $89.7 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Xpdzbk | $40.2 Bil | |
MRNA
| Moderna Inc | Mqym | $30.5 Bil | |
ARGX
| argenx SE ADR | Pkzwh | $27.3 Bil | |
BNTX
| BioNTech SE ADR | Mrbwt | $23.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vxmpc | $21.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nywfqm | $17.8 Bil | |
INCY
| Incyte Corp | Ngwvc | $12.3 Bil |